Chest
Original Research: Genetic and Developmental DisordersCORK Study in Cystic Fibrosis: Sustained Improvements in Ultra-Low-Dose Chest CT Scores After CFTR Modulation With Ivacaftor
Section snippets
Methods
All patients with CF aged 6 years or older with at least one copy of the G551D mutation attending Cork CF Centre began ivacaftor treatment after March 2013 and were followed prospectively for a mean follow-up of 12 months. The prevalence of the G551D mutation at Cork CF Centre is 23%, with 51 of 220 patients carrying at least one copy of the G551D mutation. Thirty-three patients with the G551D mutation consented to participate. Eight children were too young to receive ivacaftor, six patients
Clinical Findings
Twenty adults and 13 pediatric patients participated. Table 1 summarizes baseline characteristics. The mean age of the cohort was 21.6 years, and 70% were male participants. The mean baseline FEV1 % predicted was 75.21% (SD, 20.7). The mean baseline sweat chloride level was 101 mmol/L (SD, 14.7). The majority of patients (85%) had the F508del mutation as a second mutation. One patient was homozygous for the G551D mutation. All other patients had a class I or II mutation as the second mutation.
Discussion
This is the first study to use ultra-low-dose chest CT scanning (mean dose, 0.08 mSv per scan) to serially examine the ivacaftor response over a 1-year period, allowing an assessment of the key mechanisms underlying clinical response and assessing its utility in a clinical setting to monitor CFTR modulatory therapy response. Significant improvements in ultra-low-dose chest CT scans were observed early, after 3 months of treatment, with further improvements noted after 1 year of therapy. The
Conclusions
This study demonstrates sustained improvement after ivacaftor treatment across multiple modalities of assessment, including multiple clinical parameters, ultra-low-dose chest CT imaging, blood inflammatory markers, and the lung microbiome. It suggests the potential utility of ultra-low-dose chest CT imaging as an approach for assessing treatment response.
Acknowledgments
Author contributions: N. J. R., F. S., J. A. E., M. M. M., and B. J. P. contributed to study design. N. J. R., G. G. E., M. T., D. Mooney, D. Mullane, M. C., G. O., D. M. M., O. J. O., C. A. S., M. M. T., J. A. E., M. M. M., J. S. E., and B. J. P. contributed to data acquisition, analysis, and interpretation. All authors contributed to drafting the work and final approval.
Financial/nonfinancial disclosures: The authors have reported to CHEST the folllwing: J. S. E. reports grants, personal
References (41)
- et al.
Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation
J Cyst Fibros
(2014) - et al.
The relative frequency of CFTR mutation classes in European patients with cystic fibrosis
J Cyst Fibros
(2014) - et al.
Computed tomography correlates with improvement with ivacaftor in cystic fibrosis patients with G551D mutation
J Cyst Fibros
(2015) - et al.
Development and validation of The Cystic Fibrosis Questionnaire in the United States: a health-related quality-of-life measure for cystic fibrosis
Chest
(2005) - et al.
Validation and comparison of two multiplex technologies, Luminex® and Mesoscale Discovery, for human cytokine profiling
J Immunol Methods
(2009) - et al.
Ivacaftor potentiation of multiple CFTR channels with gating mutations
J Cyst Fibros
(2012) - et al.
Radiologic imaging in cystic fibrosis: cumulative effective dose and changing trends over 2 decades
Chest
(2012) - et al.
Effects of treatment in the levels of circulating cytokines and growth factors in cystic fibrosis and dialyzed patients by multi-analytical determination with a biochip array platform
Cytokine
(2013) - et al.
Interleukin-8 in whole blood and clinical status in cystic fibrosis
Cytokine
(2005) - et al.
A neutrophil intrinsic impairment affecting Rab27a and degranulation in cystic fibrosis is corrected by CFTR potentiator therapy
Blood
(2014)
Alterations in blood leukocytes of G551D-bearing cystic fibrosis patients undergoing treatment with ivacaftor
J Cyst Fibros
A CFTR potentiator in patients with cystic fibrosis and the G551D mutation
N Engl J Med
Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation
Am J Respir Crit Care Med
Cystic fibrosis: a worldwide analysis of CFTR mutations—correlation with incidence data and application to screening
Hum Mutat
Clinical Mechanism of the Cystic Fibrosis Transmembrane Conductance Regulator potentiator ivacaftor in G551D-mediated cystic fibrosis
Am J Respir Crit Care Med
Standardisation of spirometry
Eur Respir J
Development of low-dose protocols for thin-section CT assessment of cystic fibrosis in pediatric patients 1
Radiology
Cystic fibrosis: scoring system with thin-section CT
Radiology
Multisite comparison of high-sensitivity multiplex cytokine assays
Clin Vaccine Immunol
Practical innovations for high-throughput amplicon sequencing
Nat Methods
Cited by (69)
Potential systemic effects of acquired CFTR dysfunction in COPD
2024, Respiratory MedicineThe Impact of Highly Effective Modulator Therapy on Cystic Fibrosis Microbiology and Inflammation
2022, Clinics in Chest Medicine
FUNDING/SUPPORT: This work received funding from the European Commission for CFMATTERS [Grant agreement 603038].